Reference
1. Alesha A Thai 1 , B.J.S., Lecia V Sequist 2 , Justin F Gainor 2 ,
Rebecca S Heist 3, Lung cancer. Lancet, 2021,.398 (10299): p. 535-554.
2. Tatiana V Denisenko 1 , I.N.B., Boris Zhivotovsky 2 3, Cell
death-based treatment of lung adenocarcinoma. 2018 Jan
25;9(2) : p.:117.
3. Psallidas, I., et al., Malignant pleural effusion: from bench
to bedside. European Respiratory Review An Official Journal of the
European Respiratory Society, 2016. 25 (140): p. 189.
4. Hegde, P.S., J.J. Wallin, and C. Mancao. Predictive markers of
anti-VEGF and emerging role of angiogenesis inhibitors as
immunotherapeutics . in Seminars in Cancer Biology . 2017.
5. Wu, J., et al., Synergic effect of PD-1 blockade and endostar
on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung
carcinoma mouse model. Biomed Pharmacother, 2020. 125 : p.
109746.
6. Wu, H., et al., The Serum Tumor Markers in Combination for
Clinical Diagnosis of Lung Cancer. Clin Lab, 2020. 66 (3).
7. Bi, H., et al., Association of CEA, NSE, CYFRA 21-1, SCC-Ag,
and ProGRP with Clinicopathological Characteristics and Chemotherapeutic
Outcomes of Lung Cancer. Lab Med, 2023. 54 (4): p. 372-379.
8. Bes-Scartezini, F. and R. Saad Junior, Prognostic assessment of
tumor markers in lung carcinomas. Rev Assoc Med Bras (1992), 2022.68 (3): p. 313-317.
9. Expert Committee on Vascular Targeted Therapy,
C.S.o.C.O.E.C.o.N.-S.C.L.C., Chinese Society of Clinical Oncology and
E.G.o.A.-A.D.T.f.N.-S.C.L.C.o.t.C.S.o.C. Oncology, Anti-angiogenic
drug therapy for advanced non-small cell lung cancer Chinese Expert
Consensus (2022 Edition). Natl Med J China,, 2022. December
27,Vol. 102, : p. No. 48.
10. Shuquan, M.C.L.H.a.H.G.M.Z.H.X.H.L.W., Analysis of triple
multiple primary malignant neoplasms. Guangzhou Medicine, 2023.January, Vol. 54, : p. No. 1.
11. Expert Committee on Vascular Targeted Therapy of the Chinese Society
of Clinical Oncology, E.C.o.N.-S.C.L.C.o.t.C.S.o.C.O., Expert Group on
Anti-Angiogenic Drug Therapy for Non-Small Cell Lung Cancer of the
Chinese Society of Clinical Oncology., Chinese Expert Consensus on
Anti-Angiogenic Drug Therapy for Advanced Non-Small Cell Lung Cancer
(2020 Edition). 2020: p. 2020,42(12):1063-1077. .
12. Åsa Kristina Öjlert 1 , A.R.H., Daniel Nebdal The immune
microenvironment in non‐small cell lung cancer is predictive of
prognosis after surgery. Molecular Oncology, 2019. 13 (5).
13. Chen, K., et al., Immune microenvironment features and
efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients
with EGFR or HER2 exon 20 insertions. Thoracic Cancer, 2020: p. 2021
Jan;12(2):218-226.
14. Su, D., et al., Tumor Immune Microenvironment Characteristics
and Their Prognostic Value in Non-Small-Cell Lung Cancer. Frontiers in
Oncology, 2021. 11 : p. 634059.
15. Mazzaschi, G., et al., Therapeutic Outcomes and Clinical
Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations:
A Multicenter Real-life Retrospective Study. Clin Lung Cancer, 2022.